DIA420.55-0.96 -0.23%
SPX5,892.58+6.03 0.10%
IXIC19,146.81+136.72 0.72%

Teladoc Health First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St·05/06/2025 10:38:12
Listen to the news

Teladoc Health (NYSE:TDOC) First Quarter 2025 Results

Key Financial Results

  • Revenue: US$629.4m (down 2.6% from 1Q 2024).
  • Net loss: US$93.0m (loss widened by 14% from 1Q 2024).
  • US$0.53 loss per share (further deteriorated from US$0.49 loss in 1Q 2024).
Our free stock report includes 1 warning sign investors should be aware of before investing in Teladoc Health. Read for free now.
earnings-and-revenue-growth
NYSE:TDOC Earnings and Revenue Growth May 6th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Teladoc Health Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) missed analyst estimates by 58%.

Looking ahead, revenue is forecast to grow 1.5% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Healthcare Services industry in the US.

Performance of the American Healthcare Services industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 1 warning sign for Teladoc Health you should be aware of.

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit:  https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language

English

©2025 Webull Securities Limited. All rights reserved.